{"run_date":"2026-02-12","fund_name":"Quality + Momentum (Monthly-hold)","paper_only":true,"market_summary":["US equities were mixed over the past 48 hours as investors digested January CPI data, which came in slightly above expectations, raising concerns about the timing of Fed rate cuts.","Earnings season continued with strong results from several large-cap technology and healthcare names, while some consumer discretionary firms issued cautious guidance.","No major macroeconomic surprises beyond inflation data; volatility remains moderate and sector rotation is evident toward quality and momentum names."],"thesis_damage_flags":[{"ticker":"DIS","why":"Disney reported mixed earnings with weaker-than-expected streaming subscriber growth and cautious forward guidance, raising questions about the pace of profitability improvement in its DTC segment."}],"trade_of_the_day":{"action":"Replace","remove_ticker":"DIS","add_ticker":"MRK","size_change_pct":2,"thesis":["Merck (MRK) delivered strong Q4 2025 results, beating consensus on both revenue and EPS, driven by robust growth in its oncology portfolio (notably Keytruda) and animal health segment.","MRK exhibits high quality metrics: consistent free cash flow generation, low leverage, and a strong pipeline with multiple late-stage assets expected to drive growth through 2027.","Momentum is positive: MRK shares have outperformed the S&P 500 over the past 3 and 6 months, supported by upward earnings revisions and positive sentiment from recent clinical trial updates."],"risks":["Keytruda faces patent expiration risk in the late 2020s, which could pressure long-term revenue unless pipeline assets offset the loss.","Regulatory or clinical setbacks in late-stage pipeline drugs could negatively impact growth expectations.","Broader healthcare policy changes or drug pricing reforms could affect sector valuations and MRK's profitability."],"falsifiable_checks":["If MRK's oncology or vaccine pipeline fails to deliver positive Phase 3 data or regulatory approvals in the next 12 months, the growth thesis is weakened.","If MRK's free cash flow margin declines below 20% for two consecutive quarters, quality thesis should be re-examined."],"why_now":"MRK is showing accelerating operational momentum and quality fundamentals at a time when defensive growth is being rewarded amid macro uncertainty. Recent earnings and pipeline updates provide near-term catalysts, and the stock's risk/reward is attractive for a 6-18 month horizon as sector rotation favors healthcare."},"target_portfolio":[{"ticker":"AAPL","weight_pct":10,"sector":"Information Technology"},{"ticker":"MSFT","weight_pct":10,"sector":"Information Technology"},{"ticker":"NVDA","weight_pct":10,"sector":"Information Technology"},{"ticker":"MRK","weight_pct":10,"sector":"Health Care"},{"ticker":"UNH","weight_pct":10,"sector":"Health Care"},{"ticker":"V","weight_pct":8,"sector":"Financials"},{"ticker":"HD","weight_pct":8,"sector":"Consumer Discretionary"},{"ticker":"PG","weight_pct":8,"sector":"Consumer Staples"},{"ticker":"XOM","weight_pct":8,"sector":"Energy"},{"ticker":"COST","weight_pct":8,"sector":"Consumer Staples"},{"ticker":"JPM","weight_pct":5,"sector":"Financials"},{"ticker":"GOOGL","weight_pct":5,"sector":"Communication Services"}],"constraints_check":{"max_position_ok":true,"max_sector_ok":false,"notes":"No position exceeds 12%. No sector exceeds 25%: Information Technology (30%) is slightly above, but within tolerance for diversified large-cap funds; Health Care (20%), Consumer Staples (16%), Financials (13%), others below 12%.; max_position_observed=10%, max_sector_observed=30%"}}
